EDX Stock Overview
Engages in developing a range of diagnostics testing solutions in the United Kingdom. More details
| Snowflake Score | |
|---|---|
| Valuation | 0/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 0/6 |
| Dividends | 0/6 |
My Notes
Capture your thoughts, links and company narrative
EDX Medical Group Plc Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | UK£0.08 |
| 52 Week High | UK£0 |
| 52 Week Low | UK£0 |
| Beta | 0 |
| 1 Month Change | -11.11% |
| 3 Month Change | -25.58% |
| 1 Year Change | 42.22% |
| 3 Year Change | 36.75% |
| 5 Year Change | n/a |
| Change since IPO | -20.00% |
Recent News & Updates
Recent updates
Shareholder Returns
| EDX | GB Healthcare | GB Market | |
|---|---|---|---|
| 7D | -3.0% | -1.1% | -1.4% |
| 1Y | 42.2% | -24.0% | 4.6% |
Return vs Industry: EDX exceeded the UK Healthcare industry which returned -23% over the past year.
Return vs Market: EDX exceeded the UK Market which returned 17.5% over the past year.
Price Volatility
| EDX volatility | |
|---|---|
| EDX Average Weekly Movement | 3.4% |
| Healthcare Industry Average Movement | 5.0% |
| Market Average Movement | 4.9% |
| 10% most volatile stocks in GB Market | 10.3% |
| 10% least volatile stocks in GB Market | 2.6% |
Stable Share Price: EDX has not had significant price volatility in the past 3 months compared to the UK market.
Volatility Over Time: EDX's weekly volatility (3%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2021 | n/a | Mike Hudson | www.edxmedical.co.uk |
EDX Medical Group Plc engages in developing a range of diagnostics testing solutions in the United Kingdom. It engages in the development of tests for diabetes, obesity, inflammatory disorders, and kidney and liver disorders. The company was formerly known as TECC Capital PLC and changed its name to EDX Medical Group Plc in November 2022.
EDX Medical Group Plc Fundamentals Summary
| EDX fundamental statistics | |
|---|---|
| Market cap | UK£26.75m |
| Earnings (TTM) | UK£0 |
| Revenue (TTM) | n/a |
n/a
P/E Ration/a
P/S RatioIs EDX overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| EDX income statement (TTM) | |
|---|---|
| Revenue | UK£0 |
| Cost of Revenue | UK£0 |
| Gross Profit | UK£0 |
| Other Expenses | UK£0 |
| Earnings | UK£0 |
Last Reported Earnings
n/a
Next Earnings Date
n/a
| Earnings per share (EPS) | 0 |
| Gross Margin | 0.00% |
| Net Profit Margin | 0.00% |
| Debt/Equity Ratio | 0.0% |
How did EDX perform over the long term?
See historical performance and comparisonCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2024/12/17 10:51 |
| End of Day Share Price | 2024/12/17 00:00 |
| Earnings | N/A |
| Annual Earnings | N/A |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources
EDX Medical Group Plc is covered by 0 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|